Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244819 | PMC |
| http://dx.doi.org/10.3324/haematol.2021.280394 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.
Blood Adv
October 2024
Department of Hematology and Oncology, Dana Farber/Partners Cancer Care, Harvard Medical School, Boston, MA.
Optimal therapy for the growing number of patients with lenalidomide (LEN)-refractory multiple myeloma in their first relapse remains poorly defined. We therefore undertook a randomized phase 2 study to evaluate the efficacy and safety of combining the oral proteasome inhibitor ixazomib (IXA) with pomalidomide (POM) and dexamethasone (DEX) in this patient population. The overall response rate (ORR) for POM-DEX was 43.
View Article and Find Full Text PDFEfficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Front Oncol
May 2024
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Article Synopsis
- The study aimed to determine the best dose of selinexor when combined with pomalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM).
- In trials, two doses (40 mg and 60 mg) were assessed, showing overall response rates of 50% and 65%, respectively, with better long-term responses seen in the lower dose group (SPd-40).
- The SPd-40 regimen demonstrated a more favorable risk-benefit profile compared to SPd-60, indicating it may be the optimal dose due to its efficacy and tolerability.
Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03.
Br J Haematol
September 2024
Service Hématologie, Toulouse University Hospital, Toulouse, France.
Therapeutic strategies for patients with newly diagnosed multiple myeloma (NDMM) have considerably improved during the last 10 years. The IFM2014-03 trial proposed an all-oral triplet induction/consolidation regimen in transplant-eligible NDMM patients, followed by lenalidomide maintenance. Induction consisted of three 21-day cycles of ixazomib, lenalidomide and dexamethasone (IRd), before high-dose Melphalan with transplant followed by eight 28-day cycles of IRd consolidation before 13 cycles of lenalidomide maintenance.
View Article and Find Full Text PDFIxazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study.
EClinicalMedicine
February 2024
Department of Hematology, The Eighth Medical Center of Chinese PLA General Hospital, Beijing, China.
Article Synopsis
- This study looked at how well two treatments (IRd and IDd) work for older, frail patients with a type of cancer called multiple myeloma.
- 120 patients aged 65 and older participated and received different combinations of medicines to see which worked better and was safer.
- Results showed that both treatments helped many patients, but there were different rates of side effects and how long patients stayed healthy after treatment.
Dual-targeted regimens for the frontline treatment of CLL.
Hematology Am Soc Hematol Educ Program
December 2023
Fred Hutchinson Cancer Center, University of Washington, Division of Medical Oncology, Seattle, WA.
The treatment landscape of chronic lymphocytic leukemia (CLL) has evolved considerably over the past decade due to the development of effective novel agents with varying mechanisms of action, including Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL2) inhibitors. Extrapolating upon the success of anti-CD20-directed chemoimmunotherapy, a dual-targeted approach has been explored in treatment-naive patients with CLL. Anti-CD20 monoclonal antibody combinations with BTK inhibitors as well as BCL2 inhibitors have demonstrated superiority over traditional cytotoxic chemoimmunotherapy regimens such as fludarabine, cyclophosphamide, and rituximab; bendamustine-rituximab; and obinutuzumab-chlorambucil.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!